- Pressemitteilung BoxID 65579
New from Old
Novel tuberculosis vaccine in Germany in clinical phase
VPM coordinates application-oriented development of vaccines. The organisation is a public-private partnership established by the Federal Ministry of Education and Research (BMBF) and Helmholtz Centre for Infection Research in 2002. " We ensure that the outstanding results of basic science are actually used for the good of mankind and make their way into use," says the Clinical Project Manager Hans von Zepelin. In this, the superb contacts enjoyed by VPM within German science prove a great aid, as the Scientific and Technical Services Manager at the Helmholtz Centre for Infection Research, Rudi Balling, states: "VPM knows exactly where promising projects can be found. With their assistance we, the researchers, can show that our ideas are helping people to stay healthy."
With the financial support of the BMBF VPM was able to licence the novel tuberculosis vaccine from the Max Planck Institute for Infection Biology. The scientific foundation was established in this institute by its Founding Director Stefan H.E. Kaufmann. "The new vaccine is based on the most administered live-vaccine worldwide: Bacille Calmette-Guérin (BCG). However, BCG often fails to display effects anymore. We wanted to sharpen the blunted weapon that is BCG once again."
How this was achieved is described by Leander Grode, at that time a research assistant with Stefan H.E. Kaufmann and now Project Manager at VPM: "The weakened vaccine was genetically modified in such a way to ensure that it is no longer able to hide from the human immune system and even stimulates the body's own defences now." For that a gene of a different bacterium, Listeria, was inserted into the vaccine. "Macrophages of the human immune system take up the vaccine immediately. There it ends up in phagosomes", says Grode. "Due to the genetic modification the bacteria can leave the phagosomes and are then present in the middle of the immune cell - this alarms the rest of the immune system, which is then armed to repel real tuberculosis pathogens."
Diese Pressemitteilungen könnten Sie auch interessieren
Wenn der Alltag zu viel abverlangt, wenn wir nicht über die Runden kommen, es einfach nicht schaffen; wenn wir das Gefühl haben, neben uns zu...
Cannabis als Medizin: Deutsche Schmerzgesellschaft e. V. begrüßt heutigen Beschluss des Deutschen Bundestags zu Cannabis auf Rezept
Schmerzpräsident Prof. Dr. Martin Schmelz: „Ein wichtiger Meilenstein für Patienten und Therapeuten ist erreicht – jetzt kommt es auf eine gute...
Seit Wochen wird Frankreich von einer schweren Grippewelle überrollt, die in Krankenhäusern bereits über 50 Todesopfer gefordert hat. Auch in...